title: Bevacizumab (Avastin) for retinopathy of prematurity: wrong dose, wrong drug, or both?
authors.forename: Robert L
authors.initials: RL
authors.lastname: Avery
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects*; D000068258:Bevacizumab; D006300:Health Services Misuse; D006801:Humans; D007231:Infant, Newborn; D056687:Off-Label Use; D012178:Retinopathy of Prematurity / Q000188:drug therapy*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab